341-69-5

Applied Filters:

Keyword:'341-69-5'

Showing 1-4 of 4 results for "341-69-5" within Papers

Pharmacokinetics of cefuroxime in infants and neonates undergoing cardiac surgery.

Ralph Gertler et al.

British journal of clinical pharmacology, 84(9), 2020-2028 (2018-05-16)

Very little data exist regarding the effect of cardiopulmonary bypass (CPB) on cefuroxime (CXM) pharmacokinetics in children less than one year of age. 50 mg kg-1 CXM i.v. after induction were followed by 75 mg kg-1 into the CPB circuit. In 42 patients undergoing

Cancer Familial Aggregation (CFA) and G446A polymorphism in ARLTS1 gene.

Bartłomiej Masojć et al.

Breast cancer research and treatment, 99(1), 59-62 (2006-03-30)

ARLTS1--a member of ADP-ribosylation factor family, is a newly described candidate tumour suppressor gene. Recent studies show that a nonsense polymorphism, G446A (Trp149Stop), in ARLTS1 gene is significantly more frequent in familial cancer cases than in sporadic cancer cases. This

Insulin Promoter Factor 1 variation is associated with type 2 diabetes in African Americans.

Mohammad A Karim et al.

BMC medical genetics, 6, 37-37 (2005-10-19)

Defective insulin secretion is a key defect in the pathogenesis of type 2 diabetes (T2DM). The beta-cell specific transcription factor, insulin promoter factor 1 gene (IPF1), is essential to pancreatic development and the maintenance of beta-cell mass. We hypothesized that

Modification of the coronary artery disease risk associated with the presence of traditional risk factors by insertion/deletion polymorphism of the ACE gene.

Pawel Niemiec et al.

Genetic testing, 11(4), 353-359 (2008-02-26)

Cigarette smoking, hypercholesterolemia, and obesity influence the renin-angiotensin system (RAS) functions including an increased synthesis of the angiotensin I converting enzyme (ACE). Thus in the present work we explore the interactions of the ACE gene insertion/deletion (I/D) polymorphism and traditional

Page 1 of 1